| Drug Type Trispecific T-cell engager (TriTE) | 
| Synonyms SSS59 | 
| Target | 
| Action inhibitors, stimulants | 
| Mechanism CD28 inhibitors(T-cell-specific surface glycoprotein CD28 inhibitors), CD3 stimulants(T cell surface glycoprotein CD3 stimulants), MUC17 inhibitors(mucin 17, cell surface associated inhibitors) | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication- | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhasePhase 1 | 
| First Approval Date- | 
| Regulation- | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Advanced cancer | Phase 1 | China  | 25 Apr 2025 | 






